Compare Pfizer with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs NOVARTIS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER NOVARTIS PFIZER/
NOVARTIS
 
P/E (TTM) x 36.1 517.1 7.0% View Chart
P/BV x 6.1 29.0 21.0% View Chart
Dividend Yield % 0.6 1.5 36.8%  

Financials

 PFIZER   NOVARTIS
EQUITY SHARE DATA
    PFIZER
Mar-19
NOVARTIS
Mar-19
PFIZER/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,840980 391.8%   
Low Rs2,080600 346.6%   
Sales per share (Unadj.) Rs455.0198.7 228.9%  
Earnings per share (Unadj.) Rs93.821.0 447.3%  
Cash flow per share (Unadj.) Rs109.422.3 491.5%  
Dividends per share (Unadj.) Rs22.5010.00 225.0%  
Dividend yield (eoy) %0.81.3 60.1%  
Book value per share (Unadj.) Rs658.2307.5 214.1%  
Shares outstanding (eoy) m45.7524.69 185.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.54.0 163.6%   
Avg P/E ratio x31.637.7 83.8%  
P/CF ratio (eoy) x27.135.5 76.2%  
Price / Book Value ratio x4.52.6 175.0%  
Dividend payout %24.047.7 50.3%   
Avg Mkt Cap Rs m135,42019,508 694.2%   
No. of employees `0002.60.6 452.8%   
Total wages/salary Rs m3,2381,171 276.5%   
Avg. sales/employee Rs Th7,911.48,445.4 93.7%   
Avg. wages/employee Rs Th1,230.92,015.7 61.1%   
Avg. net profit/employee Rs Th1,630.7891.0 183.0%   
INCOME DATA
Net Sales Rs m20,8154,907 424.2%  
Other income Rs m1,674783 213.9%   
Total revenues Rs m22,4895,689 395.3%   
Gross profit Rs m5,712123 4,651.5%  
Depreciation Rs m71432 2,245.0%   
Interest Rs m7316 458.5%   
Profit before tax Rs m6,599858 769.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,309340 679.0%   
Profit after tax Rs m4,291518 828.8%  
Gross profit margin %27.42.5 1,096.5%  
Effective tax rate %35.039.6 88.3%   
Net profit margin %20.610.6 195.4%  
BALANCE SHEET DATA
Current assets Rs m27,1678,055 337.3%   
Current liabilities Rs m8,9171,850 482.0%   
Net working cap to sales %87.7126.4 69.3%  
Current ratio x3.04.4 70.0%  
Inventory Days Days6845 150.6%  
Debtors Days Days3034 88.8%  
Net fixed assets Rs m8,862150 5,915.8%   
Share capital Rs m458123 370.7%   
"Free" reserves Rs m29,6567,469 397.1%   
Net worth Rs m30,1137,592 396.7%   
Long term debt Rs m250-   
Total assets Rs m39,4009,824 401.0%  
Interest coverage x91.554.9 166.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 105.8%   
Return on assets %11.15.4 203.9%  
Return on equity %14.26.8 208.9%  
Return on capital %22.111.5 192.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42858 743.6%   
Fx outflow Rs m7861,326 59.3%   
Net fx Rs m-358-1,269 28.2%   
CASH FLOW
From Operations Rs m978-1,943 -50.3%  
From Investments Rs m3512,742 12.8%  
From Financial Activity Rs m-1,099-298 368.4%  
Net Cashflow Rs m231501 46.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 4.9 1.6 306.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 21.5 110.2%  
Shareholders   85,207 41,647 204.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DR. REDDYS LAB  STERLING BIOTECH  NATCO PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 205 Points Lower; Power and Realty Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jan 21, 2020 03:35 PM

TRACK PFIZER

PFIZER - JUBILANT LIFE SCIENCES COMPARISON

COMPARE PFIZER WITH

MARKET STATS